At a Glance
Mycosis fungoides is a form of primary cutaneous T-cell lymphoma. Mycosis fungoides is characterized by evolution of skin patches, plaques, and tumors, which often prompt a skin biopsy.
The histologic diagnosis is difficult in the early stages of mycosis fungoides. Skin biopsies classically show epidermotropic (lymphocytes infiltrating the epidermis) neoplastic T lymphocytes, with a dermal lymphoid infiltrate of varying intensity. Immunohistochemical stains for T-cell antigen expression on the skin biopsy may be helpful and classically demonstrate the lymphocytes to be CD4 positive but CD7 negative. Paraffin embedded tissue may be sent for T-cell receptor gene rearrangement detection by polymerase chain reaction (PCR) to prove the clonality/neoplastic nature of the T cells. The presence of histologic transformation, defined as greater than 25% large lymphoid cells, which may also be CD 30 positive, should also be assessed.
What Tests Should I Request to Confirm My Clinical Dx? In addition, what follow-up tests might be useful?
Patients will typically be referred to dermatologists or oncologists specialized in the treatment of cutaneous T-cell lymphomas. Mycosis fungoides may be an indolent disease. The most important factors for prognosis are the extent of cutaneous disease and extracutaneous spread, the detection of histologic transformation as described, and other indicators of tumor burdens, such as serum LDH.
Clinical staging systems incorporate pathologic assessment of clinically suspicious lymph nodes (>1.5 cm, involving excisional biopsies), for the number of abnormal lymphocytes: none, scattered atypical and large lymphocytes with cerebriform nuclei, or clusters and sheets of cells with replacement of lymph node architecture. Quantitation of neoplastic T lymphocytes within the peripheral blood (Sezary cells) is also performed, either by manual differential, flow cytometry, or both. A count of 1000 cells per micrometer is the cutoff between clinical stages III and IV. A more aggressive histologic variant of mycosis fungoides, "folliculotropic mycosis fungoides," predominantly involves the head and neck.
Copyright © 2017, 2013 Decision Support in Medicine, LLC. All rights reserved.
No sponsor or advertiser has participated in, approved or paid for the content provided by Decision Support in Medicine LLC. The Licensed Content is the property of and copyrighted by DSM.
Sign Up for Free e-newsletters
- Hodgkin Lymphoma Survivorship Marked by Periods of Actionable Distress
- Dose-Escalation Mitigates Risk of Grade 3/4 Adverse Events With Ruxolitinib for Myelofibrosis
- Stem Cell Transplantation Superior to Chemotherapy for Relapsed/Refractory DLBCL, Follicular Lymphoma
- Patients and Caregivers Worry About Cost of Cancer Care
- Open Hysterectomy Survival Rates Edge Minimally Invasive Procedures for Cervical Cancer
- Navigating Prostate Cancer: A Patient's Experience From Diagnosis to Survivor
- Cell Phones and Cancer Risk (Fact Sheet)
- How Likely Are Oncologists to Refer for Palliative Care? Depends on Their Age
- Use of Corticosteroids With PD-1 or PD-L1 Inhibitors Associated With Poorer Outcomes in NSCLC
- Chemoimmunotherapy Increases Survival in Triple-Negative Breast Cancer
- Risk for Colon Cancer, Osteogenic Sarcoma Higher With Presence of Diamond-Blackfan Anemia
- G-CSF Support Increases Overall Survival, But Risk of Secondary Malignancies Also Higher
- Report From Childhood Cancer Survivor Study Identifies Long-Term Risks for VTE
- The Effect of Intravenous Hydration Strategy on Plasma Methotrexate Clearance During Intravenous High-dose Methotrexate Administration in Pediatric Oncology Patients
- Outcomes Worse for Minimally Invasive Hysterectomy vs Open Surgery
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|